Comparing two drug combos for first-line lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous non-small cell lung cancer that is advanced or has spread and can't be cured.
- You haven't received any previous cancer treatment for this advanced stage.
- You are between 18 and 75 years old.
- You are in fairly good health, able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor outside the brain that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new treatment that combines a drug called SYS6010 with an immunotherapy (Enlonstobart) compared to the usual immunotherapy plus chemo for advanced lung cancer. The goal is to see if this combo works better and helps people with PD-L1 positive lung cancer live longer and feel better.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This study tests a new drug called ABBV-1480 combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see if it works as well as or better than the current standard treatment, pembrolizumab (also known as Keytruda) with chemotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.